Cullinan Therapeutics, Inc.
US ˙ NasdaqGS ˙ US2300311063

SecurityCGEM / Cullinan Therapeutics, Inc.
InstitutionAlgert Global Llc
Latest Disclosed Ownership109,731 shares
Latest Disclosed Value $ 1,559
Algert Global Llc reports 32.47% decrease in ownership of CGEM / Cullinan Therapeutics, Inc.

On May 14, 2026 - Algert Global Llc filed a 13F-HR form disclosing ownership of 109,731 shares of Cullinan Therapeutics, Inc. (US:CGEM) valued at $1,559,278 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 162,501 shares of Cullinan Therapeutics, Inc.. This represents a change in shares of -32.47% during the quarter. The current value of the position is $1,669,009 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F CULLINAN THERAPEUTICS COM 230031106 109,731 -52,770 -32.47 2 0.00 0.0235
2026-02-17 2025-12-31 13F CULLINAN THERAPEUTICS COM 230031106 162,501 -73,591 -31.17 2 0.00 0.0262
2025-11-14 2025-09-30 13F CULLINAN THERAPEUTICS COM 230031106 236,092 20,512 9.51 1 0.00 0.0234
2025-08-14 2025-06-30 13F ULLINAN THERAPEUTICS COM 230031106 215,580 -5,850 -2.64 2 0.00 0.0340
2025-05-13 2025-03-31 13F CULLINAN THERAPEUTICS COM 230031106 221,430 178,138 411.48 2 0.0415
2025-02-14 2024-12-31 13F CULLINAN THERAPEUTICS COM 230031106 43,292 3,408 8.54 1 0.0124
2024-11-12 2024-09-30 13F CULLINAN THERAPEUTICS COM 230031106 39,884 0 0.00 1 0.0180
2024-08-15 2024-06-30 13F CULLINAN THERAPEUTICS COM 230031106 39,884 -39,796 -49.94 1 -100.00 0.0231
2024-05-15 2024-03-31 13F CULLINAN ONCOLOGY COM 230031106 79,680 38,660 94.25 1 0.0532
2024-02-14 2023-12-31 13F CULLINAN ONCOLOGY COM 230031106 41,020 24,480 148.00 0 0.0168
2023-11-13 2023-09-30 13F CULLINAN ONCOLOGY COM 230031106 16,540 16,540 0 0.0071
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.